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Abstract.  We have synthesized an antisense oligonu- 
cleotide primer that matches a  supposedly conserved 
sequence in messages for heparan  sulfate proteogly- 
cans with transmembrane orientations.  With the aid of 
this primer we have amplified partial and selected full- 
length copies of a message from human lung fibroblasts 
that codes for a novel integral membrane heparan sul- 
fate proteoglycan. The encoded protein is 198 amino- 
acids long, with discrete cytoplasmic, transmembrane, 
and amino-terminal  extracellular domains.  Except for 
the sequences that represent putative heparan sulfate 
chain attachment sites, the extracellular domain of this 
protein has a unique structure. The transmembrane and 
cytoplasmic domains,  in contrast,  are highly similar to 
the corresponding domains of fibroglyean and synde- 
can, the two cell surface proteoglycans that figured as 
models for the design of the antisense primer.  This 
similarity includes the conservation of four tyrosine 
residues, one immediately in front of the stop transfer 
sequence and three in the cytoplasmic segment,  and 
of the most proximal and most distal cytoplasmic se- 
quences. The eDNA detects a  single 2.6-kb message 
in cultured human lung fibroblasts and in a variety of 
human epithelial and fibroblastie cell lines.  Polyelonal 
and monoclonal antibodies raised against the encoded 
peptide after expression as a beta-galactosidase fusion 
protein react with the 35-kD coreprotein of a cell sur- 
face heparan sulfate proteoglycan of human lung fibro- 
blasts and decorate the surface of many cell types. We 
propose to name this proteoglyean "amphiglycan" (from 
the Greek words amphi,  "around,  on both sides of" 
and amphoo, "both") referring to its domain structure 
which extends on both sides of the plasmamembrane, 
and to its localization around cells of both epithelial 
and fibroblastic origin. 
H 
EPARAr~ sulfate proteoglycans prove to play an im- 
portant role in the regulation  of the activities and 
bioavailabilities  of a growing  number of enzymes, 
enzyme inhibitors,  adhesion molecules, and growth factors 
(Jackson et al.,  1991). Heparan sulfate  proteoglyeans  that 
form part of  the extracellular  matrix function as binding sites 
for chymase (Sayama et al.,  1987), antithrombin  III (Pejler 
et al., 1987; de Agostini et al., 1990), protease nexin (Farrell 
et al.,  1988), and FGFs (Gonzalez et al.,  1990) which may 
provide the cells with matrix-bound reservoirs of these com- 
ponents.  For basic FGF the interaction  with the heparan sul- 
fate  of the  matrix  seems  to  metabolically  stabilize  the 
cytokine (Saksela et al., 1988), and to limit its diffusion and 
availability  (Flaumenhaft et al.,  1990),  but active heparan 
sulfate  growth factor complexes can be released from the 
matrix  through  limited  proteolysis  (Saksela  and  Rifkin, 
1990) or partial degradation of the heparan sulfate residues 
(Ishal-Miehaeli  et al.,  1990).  Moreover,  the glycosamino- 
glycan in the complex seems required for the interaction  of 
the growth factor with its receptor at the cell surface (Yayon 
et al.,  1991; Rapraeger et al.,  1991). Adherent  cells, how- 
ever, also express a number of proteins at their cell surfaces 
that are substituted with heparan sulfate and that seem to en- 
gage themselves in similar interactions  as reported for the 
matrix proteoglycans,  acting as "receptors" for the same pro- 
teinase inhibitors  (Marcum et al., 1986), matrix components 
(Koda et al.,  1985; Saunders  and Bernfield,  1988; Elenius 
et al., 1990), and FGFs (Kiefer et al., 1990; Brunner et al., 
1991). This suggests that the various heparan sulfate ligands 
may also occur in a cell surface-bound pool, and that their 
interaction  with the glycosaminoglycans  of the matrix and 
cell surface may result in a tight spatial control of their activ- 
ities. 
Recently, the characterization  of a few of these cell surface 
proteins has demonstrated the heterogeneity of the cell sur- 
face proteoglycans.  Fibroglycan (Marynen  et  al.,  1989), 
syndecan (Saunders  et al.,  1989;  Mali et al.,  1990),  and 
glypican (David et al.,  1990) are structurally distinct  pro- 
teins,  with different patterns of expression, membrane as- 
sociations,  and  metabolic  fates.  Glypican  is  widely  ex- 
pressed in many different cell types, where it is linked to the 
cell surface through  phosphatidylinositol.  Fibroglycan and 
syndecan,  in  contrast,  are  transmembrane  proteins  with 
more restricted distributions  (Lories et al.,  1992).  More- 
over, in fibroblasts, where glypican is constitutively shed and 
released to the pericellular space, fibroglycan and syndecan 
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endocytosis, suggesting that each of  these proteoglycans may 
be committed to specific processes (David et al.,  1990). 
The structural analysis of these proteins has also revealed 
some shared features that may support functions or pathways 
that are common to the different heparan sulfate proteogly- 
cans. All three share a sequence of the type SGXG preceded 
by a few acidic residues, first identified in serglycin as a site 
for  substitution with glycosaminoglycan (Bourdon et al., 
1987). Fibroglycan and syndecan in addition show a remark- 
able sequence similarity in their transmembrane and cyto- 
plasmic parts. These short domains are 52 and 66% identi- 
cal, respectively, and together contain four tyrosines that 
have been conserved in the two proteins.  The function of 
these residues is unknown, but they are reminiscent of se- 
quences that have been implicated in the targeting of integral 
membrane proteins to specific membrane domains and en- 
docytotic compartments (Ktistakis et al., 1990).  Controlled 
expression of the cell surface proteoglycans in specific mem- 
brane domains could be a further way of regulating the ac- 
tivities of their associated ligands. 
The structural heterogeneity of the cell surface heparan 
sulfate proteoglycans is, however, likely to be more extensive 
than what is illustrated by the three proteins that have been 
identified so far.  In addition to glypican, fibroglycan and 
syndecan cultured human lung fibroblasts express at least 
two other heparan sulfate proteoglycans with membrane as- 
sociations (Lories et al., 1989).  Their core proteins, which 
have apparent molecular masses of 35 and 125 kD, resist a 
treatment with phospholipase C (David et al., 1990),  which 
suggests that they may belong to the category of proteogly- 
cans with transmembrane orientations. We have speculated 
that one or both of these proteoglycans would also display 
the features that are shared by fibroglycan and syndecan and 
designed oligonucleotide primers that might allow the am- 
plification of their messages. This approach has proven par- 
tially successful, leading to the isolation of cDNA clones 
coding for the 35-kD core protein. This novel cell surface 
heparan sulfate proteoglycan belongs to the same molecular 
family as fibroglycan and syndecan, but appears to be more 
widely expressed than these two proteins. 
Materials and Methods 
Isolation of the 35K-cDNA Clones 
The antisense oligonucleotide  5ATAGCTTCCTTCATCCTTCTTTC'IV_AT, 
the complement of the 48K eDNA sequence which codes for MRKKDE- 
GSY (a peptide sequence in the cytoplasmic domain of human fibroglycan 
that closely resembles the sequence MKKKDEGSY in the cytoplasmic do- 
main of syndecan), and an oligunucleotide  terminating with the sequence 
5'GAGTCTGAGAACTTT, representing  the reverse translation  of a potential 
core protein sequence (see Results), were used as primers in a polymerase 
chain reaction. The source of cDNA and reaction conditions were as re- 
ported before (David et al.,  1990),  except for the annealing temperature 
which was  set at 45~  The product of this amplitieation was blunted, 
kinased, and ligated to a dephosphorylated Sinai restricted pGEM3Z vec- 
tor. After cloning and sequencing, this polymerase chain reaction product 
was 32p-labeled by random oligonucleotide  priming and used to screen a 
human lung flbroblast eDNA library composed of 6 x  105 independent re- 
verse transcripts cloned in the lambda ZAP II vector (David et al., 1990). 
Five positive clones were plaque purified and converted to the correspond- 
ing Blueseript SK- plasmids by superinfection with R408 helper phage. 
Analysis of the cDNA Clones 
The resulting phagemids were compared by restriction mapping and by se- 
quence analysis of both ends of the inserts.  Clone 35107 was  selected, 
digested  with suitable restriction enzymes, and subeloned in Bhiescript 
SK- or pGEM3Z plasmids.  The ends of the inserts of the 35K17S clones 
were sequenced by the dideoxy  chain termination method, using super- 
coiled plasmids,  modified T7 DNA polymerase, the appropriate primers, 
and both dGTP and 7-deaza dGTP (Pharmacia LKB Biotechnolngy,  Upp- 
sala, Sweden),  covering the whole length of both strands of the parental 
clone 35107.  A search of the Genbank and EMBL databases and the se- 
quence alignment were done with the Intelligenetics program release 5.4. 
Northern Blot Analysis 
Total  RNA  was  isolated  from  cultured  cells by the acid guanidinium 
thiocyannte-phenol-chloroform  extraction method (Chomczynski and Sac- 
chi, 1987), fractionated by electrophoresis in denaturing agarose gels and 
blotted on Nylon, essentially as described before (Marynen et al., 1989). 
The blots were hybridized to the ~2p-oligolabeled insert from the 35107 
clone and washed at high stringencies as reported before (David et al., 
1990). 
Construction and Analysis of the Expression Plasmid 
A eDNA fragment spanning from the Sinai site in the 35K17 insert to the 
SalI site in the multiple cloning site of the Bluescript vector was ligated in 
a Sinai and SalI restricted pEX3 vector (Genofil, Geneva, Switzerland) and 
used to transfect POP 2136 E, Coil cells. The 35K-pEX3 transfectants and 
control cells transfacted with pEX3 vector without insert were selected at 
28~  on ampicillin plates.  Exponentially growing cultures were initiated 
from single colonies,  and induced by incubation at 42~  for 2 h. The cell 
pellets were sonicated, digested with lysozyme, extracted with 6 M urea and 
finally solubillzed  in hot SDS for analysis by electrophoresis and Western 
blotting using a  monoclonal anti-beta galactosidase antibody (Promega 
Corporation, Madison, WI). 
Preparation of  Poly- and Monoclonal 
Anti-core Protein Antibodies 
Temperature-induced  transfectant E.  Coli cells were extracted with lyso- 
zyme, 6 M urea, and 4 M guanidinium chloride as described before (Mary- 
nen et al., 1989). The insoluble residue,  consisting mostly of recombinant 
beta-galactosidase-35K  fusion protein, was sonicated in saline, mixed with 
Freund's adjuvant, and injected subcutaneously into rabbits. Blood samples 
were collected by ear bleeding.  Pooled  sera from immune animals were 
affinity purified on fusion protein that had been coupled to CN'Br-activated 
Sepharose,  and cleam:i from contaminant specificities  by incubation with 
CNBr-activated  Sepharose substituted with extract from pEX3-transfected 
E.  Coli ceils,  essentially as described before (Marynen et al.,  1989). 
Alternatively, the insoluble residue was rinsed with water, solub'flized in 
hot SDS, fractionnted by SDS-PAGE, and blotted onto pure nitrocellulose 
membranes. The blot was stained with Coomassie brilliant  blue and the seg- 
ment that contained the beta-galactosidase-35K fusion protein was excised 
from the membrane. After drying, the nitrocellulose support was solubi- 
lized in acetone and the insoluble protein was pelleted by centrifugation. 
After several rinses with acetone, the protein was sonicated in a (I:I) mix- 
ture of PBS and Freund's  adjuvant and used to immunize Balb/c mice by 
repeated  intraperituneal injection. Blood samples were collected by eye 
bleeding,  and the spleens  from immune animals were collected for the es- 
tablishment of hybridomas as described before (Deboeck et al.,  1987). 
Isolation and Analysis of the Cell 
Surface Proteoglycans 
Cell surface proteoglyeans were isolated from confluent cultured human fe- 
tal lung fibroblasts and analyzed, essentially as described before (Lories et 
al., 1989). Briefly, the cells were extracted in ice-cold 0.5% Triton X-100 
buffer in the presence of proteinase inhibitors. The hydrophobic proteogly- 
cans were purified from this extract by ion-exehs~e chromatography on 
Mono Q, incorporation into liposomes,  and gel filtration over Sepharose 
CL4B in 4 M geanidininm chloride buffer without detergent. The cell sur- 
face proteoglycan  samples were concentrated, digested with heparitinase, 
fractionated by electrophoresis in SDS-polyacrylamide  gradient gels,  and 
blotted on Z-probe membranes. The blots were incubated with the rabbit 
or murine antibodies and developed with the appropriate HRP- or alkaline 
phosphatase-conjugated  second atttibodies, by staining, using 3,3' DAB, or 
by chemiluminescence and autoradiography,  using AMPPD ('ll-opix, Bed- 
ford, Mass). The procedures for the metabolic labeling or radioiodination 
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Sepharose,  and for the immunopurification of the 8G3-reactive  proteogly- 
can on the immobilized antibody were as described before (Lories et al., 
1989). 
Immunohistochemistry 
Cultured human lung fibroblasts and cryosections of  human skin tissue were 
p~,red and treated as reported before ~avid et al., 1989), and incubated 
for 1 h with the conditioned culture medium of hybridoma F94-SG3 or with 
the antibodies F58-2E9 (anti-syndecan), F58-10H4  (anti-fibrnglycan),  and 
SI (anti-glypican) described before (De Boeck et ai.,  1987; Lories et ai., 
1989; David et al., 1990). After rinsing, the sections were further incubated 
for 1 h with an HRP conjugated rabbit anti-mouse Ig (Dakopatts,  Glostrup, 
Denmark) and stained using 3,3' DAB and hydrogen peroxide. 
Results 
Cloning of  a Novel Cell Surface Proteoglycan 
Fibroblasts express multiple heparan sulfate proteoglycans 
at their cell surfaces (Lories et al.,  1989).  At least two of 
these proteins, fibroglycan (Marynen et al., 1989) and syn- 
decan  (Lories  et  al.,  1992),  show  significant sequence 
similarities in their membrane-spanning and cytoplasmic 
domains. Their ectodomains, in contrast, are dissimilar, ex- 
cept for the sequences that have been proposed as sites for 
substitution  with  glycosaminoglycan chains  in  these  and 
other proteins (Bourdon et al.,  1987;  Mann et al.,  1990). 
Speculating that conserved cytoplasmic structures may form 
the hallmark of a specific subset of  the cell surface proteogly- 
cans,  we designed a  "universal" antisense oligonucleotide 
primer that, in conjunction with appropriate sense primers, 
might allow the specific amplification of novel fibroglycan- 
and syndecan-related  messages from the appropriate libraries. 
We used it successfully in combination with a primer that in- 
cluded the sequence GAGTCTGAGAACTTT coding for the 
peptide sequence ESENF which mimics a cluster of amino- 
acids that forms part of a glycanation site of the "serglycin 
type" (Bourdon et al.,  1987)  in syndecan. 
The polymerase chain reaction product which was ob- 
tained with this primer combination using a  fibroblast li- 
brary as a source of cDNA, was cloned and sequenced and 
potentially represented a cDNA for a novel cell surface pro- 
teoglycan. This ,,o350-bp cDNA was used to screen the li- 
brary from which it had been amplified to isolate corre- 
sponding full-length cDNA clones. Based on the restriction 
patterns and terminal sequences of the isolated clones, clone 
35K17 was selected for further subcloning (Fig. 1) and com- 
plete sequencing (Fig. 2). 
The insert of  clone 35K17 was 2613 bp long. The first ATG 
in  its  sequence  occurred  at  position  27.  Surrounded  by 
guanosines at positions  -3 and +4, this ATG occurred in 
a context favorable for the initiation of translation (Kozak, 
1989) and formed the start of an open reading frame of 594 
bases coding for a peptide sequence of 198 amino acids (Fig. 
2).  The coding sequence was terminated by a  TGA stop 
codon and followed by  1,990  bases  of 3' untranslated se- 
quence terminating with an AATAAA polyadenylation sig- 
nal and,  15 bases further, a poly A  stretch. Northern blot 
analysis of a total RNA extract from human lung fibroblasts 
using the 35K17 insert as a probe revealed a single '~2.6-kb 
message, indicating that the 35K17 sequence represented a 
near complete transcript (Fig. 3). Comparison of the 35K17 
sequence with the sequence of  the amplified cDNA indicated 
that the amplification had resulted from the "legitimate" hy- 
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Figure L Restriction map and strategy used for the sequencing of 
clone 35K17. Only the restriction sites for enzymes used in the sub- 
cloning of clone 35K17 are indicated: Sm, Sinai; X, XbaI; Hd, 
HindllI; Hc, HincH; Sa, SacI; Ss, SstI; A, AsnI; P, PvuII; St, StuI. 
The arrows indicate the direction and length of the nucleotide se- 
quences obtained from the analysis of the various 35K17s clones. 
The box represents the coding part of clone 35K17 and its shaded 
areas illustrate the sequences coding for hydrophobic peptide seg- 
ments. The position of  the single polyadenylation  signal is indicated 
by the triangle. 
bridization of the antisense primer to the target DNA se- 
quence. 
The peptide encoded by the open reading frame of the 
35K17 insert had the features of a type I integral membrane 
protein, starting with an amino-terminal hydrophobic seg- 
ment with the characteristics of a signal peptide (18 amino 
acids), followed by the presumptive extraceUular domain of 
the mature protein (127 amino acids), a membrane-spanning 
segment (25 amino acids), and a short carboxy-terminal cy- 
toplasmic  domain  (28  amino  acids).  The  peptide  had  a 
predicted molecular weight of 21,607 in the precursor form, 
and of 19,766 after removal of the signal  sequence.  The 
presumptive  ectodomain  contained  4  SG  sequences,  in 
greater or lesser proximity of acidic residues,  that could 
function as sites for the implantation of glycosaminoglycan 
chains (Bourdon et al.,  1987; Mann et al.,  1990).  Two of 
these occurred as a repeat sequence in a context reminiscent 
of the structures of proposed glycanation sites in serglycin 
and in previously identified heparan sulfate proteoglycans 
(Fig. 4). The peptide lacked recognition sequences for sub- 
stitution with N-linked oligosaccharides, but had one SST 
sequence that could serve for O-glycosylation. The ectodo- 
main also contained two dibasic sequences that could form 
a substrate for trypsin-like enzymes. Most interestingly, at 
the presumptive start of the ectodomain the predicted se- 
quence included a  stretch of 25 aminoacids (underlined in 
Fig.  2),  which  completely matched the  sequence  of the 
amino terminus of a heparan sulfate proteoglycan from rab- 
bit  aorta  endothelial cells  previously  reported  by  others 
(Castillo et al.,  1987).  Moreover,  the presumptive trans- 
membrane and cytoplasmic domains of the protein showed 
extensive sequence similarity to the corresponding domains 
of fibroglycan (73 % identity) and syndecan (53 % identity). 
This similarity included the conservation of four tyrosine 
residues (indicated by asterisks in Fig. 5). From these data 
we concluded that clone 35Kt7 indeed coded for a  novel 
David et al. Cell Surface Heparan Sulfate Proteoglycan  963 GC  GCG  CCT  TCT  CCA  GTC  CGC  GGT  GCC  ATG GCC  CCC  GCC  CGT  CTG  TTC  GCG  CTG  CTG  CTG  CTC  TTC  GTA GGC 
M  A  P  A  R  L  F  A  L  L  L  L  F  V  G 
GA GAG  ACT  GAG  GTC  ATC  GAC  CCC  CAG  GAC  CTC  CTA  GAA  GGC  CGA  TAC  TTC  TCC  GGA  GCC  CTA  CCA  GAC  CAT 
E  T  E  V  !  D  P  q  D  L  L  E  G  R  Y  F  S  G  A  L  P  D  D 
GG  CAG  GAA  TCT  GAT GAC  TTT  GAG  CTG  TCT  GGC  TCT  GGA  GAT  CTG  GAT GAC  TTG  GAA GAC  TCC  ATG ATC  GGC 
Q  E  S  D  D  F  E  L  S  G  S  G  D  L  D  D  L  E  P  S  M  I  G 
TG GTG  pCCT CTA  GAT  AAC CAT  ATC  CCT  ~AG AGG  ~A GGG  TCT  GGG  AGC  CAA GTC  CCC  TACC EGAA pCCC~G~  V  L  D  N  H  [  P  E  R  A  G  S  ￿9  G  8  Q  v 
TC pCCC([~i(~  ATC  TCA  CCC GTT  GAA GAG AGT  GAG GAT  GTG  TCC AAC AAG vGTG TCA MATG ~  ;~  ACT  GTG  $  P  V  E  E  S  E  D  V  S  N  K  ........  T_  V 
AG AGA ACG  GAG  GTC CTG  GCA  GCT  CTG  ATT GTG  GGT  GGC  ATC  GTG  GGC  ATC  CTC  TTT  GCC  GTC  TTC  CTG  ATC 
R  T  E  V  L  A  A  L  I  V  G  G  I  V  G  I  L  F  A  V  F  L  I 
TG AAG  AAG AAG GAT  GAA  GGC  AGC  TAT GAC  CTG  GGC  AAG AAA CCC  ATC  TAC  AAG  AAA GCC  CCC  ACC  AAT GAG 
K  K  K  D  E  G  S  Y  D  L  G  K  K  P  I  Y  K  K  A  P  T  N  E 
TT GTG  GGC  ACT  GGC  TTG  GAC  TTT AGC  GGG  GAG  GGA  AGC  CAG  GGG  ATT TTG  AAG  GGT  GGA  CAT  TAG GGT  AGG 
GA CTT  GTC  AGT  ATC  TCC  AGC  TCT  GAT  TAC  CTT  TGA AGT GTT  CAG  AAG AGA  CAT  TGT  CTT  CTA  CTG  TTC  TC-C 
GG  GCC  TCA  GTT  GCC  CTG  GCA  GAA AAA TGG  ATT CAA  CTT  GGC  CTT  TCT  GAA GGC  AAG ACT  GGG  ATT GGA  TCA 
AG AAT CTA  GGT  CCG  CCC  TCA  AGC  CCA  TAC  TGA  CCA  TC'C CTC  ATC  CAG  AGC  TCC  TCT  GAA  GCC  AGG  GGG  CTA 
CT  GGC  TGG  AGG  TCC  TCC  CCC  AGT GGC  CTT  CCT  CCC  TTC  CTT  TCA  CAG  CCG  GTC  TCT  CTG  CCA  GGA  AAT GGG 
TG CAC  CTT  GAG  ATG  TTT CTG  TAA ATG GGT  ACT  TGT  GAT  CAC  ACT  ACG  GGA  ATC  TCT  GTG  GTA  TAT ACC  TGG 
AA GTG  ACT  TTT GGA  AAT CAA CCT  TTT TTA TTT GGG  GGG  GAG  CAT GGG  GAA AAG  AGC  TGA GAG  TTT  ATG CTG 
TT GTA AAT CTA  TTT  TTA GTG  TTT  GTT  CGT  TTT  TTT  AAC  TGT  TCA  TTC  CTT  TGT  GCA  GAG  TGT  ATA TCT  CTG 
GT GCC  GAG  GTG  TCT  TCA  TTC  TCT  CGC  ACA  TTT  CCA  CAG  CAC  CTG  CTA  AGT  TTG  TAT TTA ATG GTT  TTT  GTT 
TG AAA ATG AGA GAA GAG  CCG  GAG  AGA TGA  TTT TTA TTA ATT TTT  TTT  TTT  TTT TTT  TTT  TTA CTA  TTT  ATA 
TT CCC  CTC  TTC  TTT CTT  TGT  TCT  CTT  TCA  TTA AAC CCC  TTC  CCC  AGT  TTT TTT TTT ATA CTT  TAA ACC  CCG 
TT  TCT  GAA  GCT  GCT  TCC  TCT  TAT AAA ATA GCT  TTT  GCC  GAA ACA  TAG  TTT  TTT TTT AGC  AGA  TCC  CAA  AAT 
GA TAT  TTG  TGT CTG  TGT  TCT  TAT AAT ATA TTA TTA TTC  TTC CTT  GGT  TCT  AGA AAA ATA CAT  AAA TAT ATT 
GT GTT  TCC AGT  TTG ATG  TTG CTG GGT  GGT  TGA  GTG AGT  GAA TTT  TCA  TGT  GGC  TGG GTG GGT  TTT  TGC CTT 
GG TGC CTT  CTG ATG GGG CTG GAA TAG TTG  AGG TGG ATG  GTT CTA CCC TTT  CTG  CCT  TCT  GTT  TGG GAC  CCA 
CT  TTC  TTC AGG CTC  TAG ~  TGT  GCT  ATC CAA  TAC  AGT AAC CAC  ATG CGG CTG  TTT AAA GTT  AAG CCA  ATT 
AA  TTC CTT  CCT  CAG  TTG CAC  TAA CCA CGT  TTC  TAG AGG CGT  CAC  TGT ATG  TAG  TTC ATG GCT ACT  GTA CTG 
CT  GTT  GGA CAG CAC  TAT  TCT  AGA GAA CTA AAC  TGG CTT AAC GAG TCA  CAG CCT  CAG CTG  TGC  TGG GAC GAC 
GG GGG GGG AAT GGG GGA C-GG CTG ATG AGG CCC CAG CTG  GGG CCT  GTT  GTC  TGG GAC CCT CCC  TCT CCT  GAG 
AG CCT  GGG CAG GTC  GTG  TCT  CCT  CCT  GAC CCC  AGT  C-GC TGC GGT  GAG GGG A.a,C CAC CCT  CCC  TTG  CTG CAC 
TC  ACC  ACT GCA ACC CAG GGT  CCC  AGC  TGG  CTG GGT CCT  CTT  CTG CCC CCA  GTG CCC  TTC  CCC  TTG  GGC TGT 
CT  GTA GGC ACC  TCT  CAC  ACT  GTT GTC TGT  TAC  TGA  TTT  TTT  TTG ATA AAA AGA  T~:~T.E~ ~C  CTG GTA  CTT 
AAA 
GGA  GTC  GCC  GAG  TCG  ATC  C 
G  V  A  E  S  I  R 
GAG  GAT  GTA GTG  GGG  CCC  G 
E  D  V  V  G  P  G 
CCT  GAA  GTT  GTC CAT  CCC  T 
P  E  V  V  H  P  L 
CTA  GAG GAG AAT GAG GTT A 
L  E  E  N  E  V  I 
~AG GGGC ;GC NAAC ATCI TTTGF  E 
CTA  CTG  CTC  ATG TAC  CGT  A 
L  L  L  M  Y  R  M 
TTC  TAC  GCG  TGA  AGC  TTG  C 
F  Y  A  * 
GTG  AGG TCA ACC TAA TAC  T 
CAG GTT  CTT CTT GAG CTT  T 
CTT  CTT  AAA CTT (:CA GTT  A 
ACG GAT  GTT GTG TGG AGT C 
GGA AGG AAC  TAG AAC CAC C 
GGC CAT TCT  AGG CTC  TTT  C 
AAA TGG ATT TAT AGA ATA T 
CCT  GGG CAA GAG TGT GGA G 
TTT  GTT  TTT  GTT  TGT  TTC T 
GCT  TTA GAT  AGG GCC TCC C 
CTC  CTC ATG GCC  TTG GCC C 
ATA ATG AAG GGG ATG GTG G 
TTT  TTC AGG AAA TAG TGT G 
TTT CTC  TTG CCC  TGT TCC  T 
GCT  GGT  GTT CTT  TGG TIT G 
AAA ATC  ACA  TAA GAT  TAA A 
ACA G(~  AGA GCA  TGT CCA  T 
OCT  TGT CTC  CCT  GGG TAG G 
AGG  GGA  GGC  CTG  GTG  GC T 
CA(; TGG  CCA  TTA GCT  CCC  G 
GTT  GGA  GTG  AGC  ACC  TCC  T 
TCT  AAA AAA AAA AAA AAA A 
Figure 2.  Sequence  of clone 
35K17 and predicted primary 
90  structure of amphiglycan. The 
22  part  of the predicted  protein 
18o  sequence  that  matches  the 
52 
amino terminus of the endo- 
270  thelial proteoglycan has been  82 
indicated by thin underlining,  360 
112  the  gap  corresponding  to  a 
450  blank  cycle  obtained  during 
142  the sequencing of the protein 
54o  (Castillo  et  al.,  1987).  The 
172  double  line  marks  the  pre- 
530  sumed  transmembrane  do- 
19a  main. The position of the four 
720  SG sequences is indicated by  81o  900  the  triangles.  The  cluster  of 
990  hydroxylated amino acids that  1080 
1170  may be O-glycosylated is indi- 
1260  1350  cated with a broken line. Resi- 
1,4o  dues  in  the  ectodomain  that 
1530 
1628  form part of dibasic sequences 
1710  180o  have been encircled. The AAT- 
1890  AAA  polyadenylation  signal  1980 
2070  is marked by the shaded box. 
2160 
22so  These sequence data are avail- 
23,0  able  from  EMBL/GenBank/  2430 
2520  DDBJ  under accession  num- 
2610 
2513  ber X67016. 
member of a distinctive family of cell surface heparan sulfate 
proteoglycans. 
Characterization of the Corresponding 
~broblast Proteoglycan 
To identify  the cellular product which corresponded  to the 
translation of the 35K  sequence,  the 35K17  insert was sub- 
cloned  in  the pEX3  prokaryotic  expression  vector and  ex- 
pressed as a beta-galactosidase  fusion protein in E. coli host 
cells (Fig. 6). This fusion protein was used to immunize rab- 
bits  and  mice,  and  to  raise  poly  and  monoclonal  antisera 
directed against the presumptive  core protein moiety of the 
recombinant peptide (Fig.  6).  The polyclonal antiserum and 
one of the selected mAbs, designated  F94-8G3,  was used to 
analyze proteoglycan  extracts  from human lung  fibroblasts 
in Western blotting experiments  (Fig.  7).  Both types of anti- 
bodies reacted with the native and heparitinase-digested  pro- 
teoglycan  fractions.  The  undigested  immunoreactive  pro- 
teoglycan  migrated  poorly  and transferred poorly  from the 
gels,  but after a treatment with heparitinase  (Fig.  7) or with 
both heparitinase  and chondroitinase  ABC  (not shown) the 
Figure 3. Northern blot anal- 
ysis of  the amphiglycan mRNA. 
10-/zg  aliquots  of total  RNA 
from human HS  683  glioma 
(lane/),  skin fibroblasts  (lane 
2),  HBL-100  breast (lane 3), 
lung  fibroblast  (lane 4),  HT- 
1080 sarcoma (lane 5), TR-14 
neuroblastoma (lane 6), HEP 
3B hepatoma (lane 7), MOLT-4 
acute lymphoblastic leukemia 
(lane 8), MG-63 osteosarcoma 
(lane  9),  A-431  epidermoid 
carcinoma (lane 10), Y79 ret- 
inoblastoma (lane//),  Tera-2 
embryonal  carcinoma  (lane 
12),  U-937  histiocytic  lym- 
phoma  (lane  13),  umbilical 
vein  endothelial  (lane  14), 
MCF-7 breast adenocarcinoma (lane 15), A-375 malignant melanoma (lane 16), IM-9 myeloma (lane 17), CaCo-2 colon adenocarcinoma 
(lane 18), and HEP (32 hepatocarcinoma (lane 19) cell cultures were fractionated in agarose gels, blotted,  and hybridized to the 35K17 
probe. 
The Journal  of Cell Biology, Volume 118, 1992  964 SYNDEC~  D  S  N  F  A  A  51 
FIBROGLYC~  D  D  Y  A  A  S  A  59 
AMPHIGLYC~  E  S  D  F  E  L  S  D  65 
IP  RAG  SQV  99 
P  R  R  P  P  T  L  376 
Q  L  A  Q  D  210 
Q  D  F  T  F  T  N  T  220 
FIBROGLYCAN  N  S  S  I  E  ....  A  ...  ~  Y  P  45 
BETAGLYCAN  A  P  S  P  G  ~  S  i 
GY  D  L 
CD44E  P  T  D  D  S 
S  S  R  S  T 
CN~'Na  r. 
O  ~TFHP 
E  A  N  T  T 
W  P  D  543 
S  184 
GY  I  194 
H  367 
P  I  R  394 
Figure 4. Comparison of putative glycanation sites in heparan sul- 
fate proteoglycans. The putative glycanation sites in amphiglycan 
are compared to similar sequences in human serglycin (Stevens et 
al.  1988), syndecan (Mali et al.,  1990), fibroglycan (Marynen et 
al., 1989), and glypican (David et al.,  1990), which are known to 
be substituted with heparin or heparan sulfate chains and, in syn- 
decan,  also with chondroitin  sulfate. They are also compared to 
similar sequences in rat betaglycan (Lopez-Casillas  et al.,  1991; 
Wang et al., 1991) and human CD44-E (Stamenkovic et al., 1991; 
Brown et al., 1991), which are primarily substituted with chondroi- 
tin sulfate but also some heparan sulfate chains. All are variations 
on a sequence motif  which includes the clustering of  acidic residues 
and SG. Two types of sequences, Acidic-XXXXSGXG and Acidic- 
XSG-Acidic, and hybrid forms of these sequences seem to occur. 
Seemingly conserved residues that appear characteristic  for these 
glycanation "cassettes" have been boxed. Small gaps have been al- 
lowed to maximize the sequence similarity. All SG sequences in the 
proteins are shown, except for serglycin (where only the start of the 
repeat is shown) and betaglycan (only the SG sequences in prox- 
imity of acidic residues).  Protein  sequencing data suggest that in 
human lung fibroblasts the serine at position  308 in the glypican 
sequence is not used for glycanation (David et al.,  1990). 
antisera stained a discrete protein band which migrated with 
an apparent molecular mass of 35 kD. In contrast,  staining 
the blots with mAb F69-3G10, an antibody that reacts with 
the unsaturated glucuronates generated by the cleavage of the 
heparan sulfate chains with heparitinase, yielded the charac- 
teristic series of  bands in this preparation, including the core 
identified by the anti-35K antibodies, the cores of fibrogly- 
Syn  245  GLLDRKEVLGGVIAOGLVGLIFAVCLVGFMLYRMKKKDEGSYSLEEPKQ~YQK  PTKQEEFYA 
Fib  138  SLFKRTEVLAAVIAGGVIGFLFAIFLILLLVYRMRKKDEGSYOLGERKPSSA  AYQKAPTK  s 
IIlllll  II  I I IIIIII II  llIllll  I|II  IIII 
,,  ~  ,,,,,,  II  I  IIIIIIII 
35K  ~39  NIFERTEVLAALIVGGIVGILFAVFLILLLMYRMKKKDEGSYDLG  KKPl  YKKAPTN EFYA 
consensus  -]f-RtEVLaavIaGG-vG-lFAvfLill]-YRMkKKDEGSYdLge-Kp----aYqKaPTk--EFYA 
Figure 5. Alignment of the terminal ectodomain,  transmembrane 
and cytoplasmic sequences of syndeean, fibroglyean and amphigly- 
can.  Gaps have been included to allow for the maximum of se- 
quence identity. The numbers  indicate the position of the start of 
these sequences in the proteins (Mali et al., 1990; Marynen et al., 
1989). The deduced consensus sequence shows a dash where the 
three sequences disagree, small lettering where only two out of the 
three show the same residue, and capital letters where the sequence 
of all three proteins  is identical. 
Figure  6.  Expression  of am- 
phiglycan as a beta galactosi- 
dasr  fusion  protein.  Clone 
35K17 was  subclonexl in the 
pEX3 prokaryotic  expression 
vector.  Lysates  of  heat-in- 
duced POP 2136 E. Coil cells 
that had been transfected with 
35FA7-pEX3 (A)  or with  an 
empty pEX3 vector (C) were 
fractionated by electrophoresis 
in  SDS-polyacrylamide  gels 
and blotted onto a nitrocellu- 
lose membrane. The membranes were inactivated and stained with 
a monoclonal anti-beta galactosidase antibody (lanes I and 2), with 
the polyclonal anti-fusionprotein antibody (lanes 3 and 4), and with 
the mAb F94-8G3  (lanes 5 and 6). 
can ('048 kD), glypican (,064 kD), and syndecan (,085 kD), 
and finally the "0125-kD core of a still unidentified, but pos- 
sibly syndecan-related heparan sulfate proteoglycan (Lories 
et al.,  1992). 
To  confirm  these  results,  mAb  8G3  was  coupled  to 
Sepharose CL4B and used to purify the immunoreactive pro- 
teoglycan from '25I-  and ssSO4--labeled cell surface proteo- 
glycan fractions from human lung fibroblasts. After the ap- 
propriate  enzyme  digestions,  analysis  of  the  iodinated 
proteoglycans by SDS-PAGE and autoradiography revealed 
multiple  coreproteins  in  the  unfractionated  samples  (not 
shown), but only a single coreprotein in the immunopurified 
proteoglycan (Fig. 8, lanes 1-4). Without enzyme treatment 
or after a digestion with only chondroitinase ABC, the 8G3- 
reactive proteoglycan barely  entered  the  gel.  The  corre- 
sponding heparitinase-digested or doubly heparitinase and 
chondroitinase ABC-treated proteoglycan samples, in con- 
trast, were entirely included in the gel and migrated as single 
discrete bands with apparent sizes of'0 35 kD. The suscepti- 
bility  of the  immunopurified  35SO4--labeled  materials  to 
heparitinase and their resistance to chondroitinase ABC also 
suggested that the proteoglycan carried mainly or only hepa- 
ran sulfate chains (Fig. 8, lanes 5-8). Heparan sulfate chains 
Figure 7. Reactivity of the cell 
surface  proteoglyeans  from 
human  lung  fibroblasts  with 
the anti-amphiglycan antibod- 
ies.  The  liposome-interca- 
latable  heparan  sulfate  pro- 
teoglycans  from human lung 
fibroblasts were left untreated 
(U) or digested with hepariti- 
nase (D), and fractionated  by 
electrophoresis  in  SDS-poly- 
acrylamide  gradient  gels. 
After  blotting  onto  Nylon 
membranes the proteoglycan 
fractions were stained with the polyclonal (a-FP) and monoclonal 
(8G3) anti-amphiglycan antibodies and with the anti-"heparan sul- 
fate stub" antibody F69-3G10 (lane 1) to reveal all coreproteins  in 
the  samples.  Undigested proteoglycans  transfer  poorly from the 
gel, but react with the antibodies as revealed by dot blot experi- 
ments (not shown). The arrowheads indicate the positions of glypi- 
can (G) and fibroglycan (F). 
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ity ofamphiglycan. Amphigly- 
can was immtmopurified from 
12SI-labeled (lanes  1-4)  or 
asSO,--labeled (lanes 5-8) cell 
surface proteoglyean fractions 
by adsorption on immobilized 
mAb  8G3  and  analyzed  by 
SDS-PAGE  and  autoradiog- 
raphy, either directly or after 
digestion  with  heparitinase 
(Hase),  chondroitinase ABC 
(Case), or both enzymes. 
isolated from these materials by alkaline-borohydride treat- 
ment migrated with K,, value of 0.51-0.54 during gelfiltra- 
tion over Sepharose CL4B, which corresponded with an av- 
erage Mr of 58-50 kD. The intact proteoglycan, in contrast, 
yielded a Ko, value of 0.28 (apparent Mr > 200), which sug- 
gested that the 35-kD protein core was substituted with sev- 
eral heparan sulfate chains. 
Expression in Other Cell ~es 
Northern blot analysis of total RNA extracts from several 
cultured cell lines using the 35K17 insert as probe revealed 
a single 2.6-kb mRNA in most of the samples (Fig. 3). Ex- 
ceptions were some cells of hematogenous origin, where no 
message could be detected. Several of the cell lines with a 
strong 35K signal had previously been found to be relatively 
low  expressors  of mRNA  for  syndecan,  fibroglycan,  or 
glypican (Lories et al., 1992). Analysis of the detergent ex- 
tracts of several of these cell lines by immuno~ot blotting 
confirmed the expression of the 8G3 epitope in these cells 
(not shown). 
Immunohistochemieally, the  8G3  epitope could be de- 
tected in both epithelial and connective tissue cells (Fig. 9). 
For example, in human skin the contours of the cells of the 
basal cell layer and of the stratum spinosum of the epidermis 
Figure 9. Expression of the cell surface proteoglycaus in human skin tissues. Sections of human skin (a-d) and whole mounts of cultured 
human skin fibroblasts (e-h) were stained using an indirect immunoperoxidase technique after incubation with either antiamphiglycan 
(a and e), antisyndecan (b and f), antifibroglycan (c and g), or antiglypican (d and h) monoclonal first antibodies. Bars, 50 #m. 
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layers of the stratum granulosum and the keratinized  cells 
were unstained (Fig. 9 a). mAbs directed against syndecan 
(Fig. 9 b) or glypican (Fig. 9 d) also stained the epidermis. 
However, the anti-syndecan  antibody (and to a lesser extent 
the anti-glypican  antibody) stained mostly areas of cell-ceU 
contact where the 8G3 antibody also stained the interface be- 
tween the basal cells and the underlying  matrix.  A  mAb 
directed against  fibroglycan,  in contrast,  stained primarily 
cells in the dermis ~ig. 9 c). Unlike the anti-syndecan,  but 
like the anti-fibroglycan  and anti-glypican  antibodies, anti- 
body 8G3 reacted also with the surface of unpermeabilized 
cultured fibroblasts  (Fig. 9, e-h), consistent with an occur- 
rence at the surface of several different cell types. These data 
suggest that the 34K core protein may have a rather ubiqui- 
tous distribution, in contrast with syndecan and fibroglycan 
which, in the adult, appear to be preferentially  expressed by 
epithelial  and fibroblastic cells, respectively. 
Discussion 
The heparan sulfate proteoglycans of the cell surface and ex- 
tracellular matrix have the potential to modulate a variety of 
processes by affecting the compartmentalization,  conforma- 
tion, and reactivities of their ligands. They catalyze the inhi- 
bition of proteinases,  stabilize and potentiate the activities of 
growth factors, and affect the localization  and translocation 
of several structural proteins and enzymes. The heparan sul- 
fate chains that mediate these effects are carried by a number 
of distinct cell surface and matrix proteins.  The present re- 
port describes the molecular cloning of a novel cell surface 
proteoglycan which we have named ~amphiglycan:  Together 
with fibroglycan and syndecan it appears to belong to a dis- 
tinctive family of integral membrane proteins that share con- 
served transmembrane and cytoplasmic domains and char- 
acteristic sequences in their ectodomains that may serve for 
the attachment of heparan sulfate chains.  These three differ- 
ent proteins may assume similar  functions  but in different 
cellular and molecular contexts. 
Direct evidence that the third member of this family is a 
heparan sulfate proteoglycan has been provided by raising 
antibodies against a recombinant version of this protein and 
demonstrating  that these antibodies react with a specific core 
protein in proteoglycan extracts from human lung fibroblasts. 
Moreover,  the predicted amino-terminal  sequence of this 
protein is identical to that of a heparan sulfate proteoglycan 
isolated some years ago by other investigators  (Castillo  et 
al., 1987) from the culture medium of an established rabbit 
aorta endothelial  cen line.  The molecular mass of the en- 
dotheliai  proteoglycan core, however, was estimated at 22 
kD,  which is smaller than  the Mr of the mature fibroblast 
core protein (35 kD) and seems to be in better agreement 
with the mass predicted from the cDNA sequence ('~20 kD). 
Whether these discrepancies reflect  extensive posttransla- 
tional modifications of the protein core in fibroblasts and the 
existence of amphiglycan variant forms is not clear. All hepa- 
ran sulfate proteoglycans of this family (syndecan, fihrogly- 
can, as well as amphiglycan)  in fibrohlasts have core protein 
sizes that appear significantly larger than predicted from the 
cDNA sequences. If explainable by glycosylation and differ- 
ences in glycosylation, then the added mass and apparent 
size differences for amphiglycan between fihroblasts and en- 
dothelial  cells should reside in O-linked residues since the 
protein contains no asparagine  that seems amenable to gly- 
cosylation but one cluster of hydroxylated amino acids that 
may serve for that purpose. O-linked carbohydrate chains 
may range in size from 1 to more than 20 sugars,  and the 
presence of even relatively short O-glycosylated sequences 
is known to have profound effects on the size and shape of 
glycoproteins (Jentoft,  1990). In this context it may also be 
noted that fibroglycan,  which has the same predicted core 
size as amphiglycan but one site for N-glycosylation and two 
serine-threonine  clusters, migrates as a 40-50-kD protein 
(Marynen et al.,  1989).  Another possibility that  may ac- 
count for the different size estimates in endothelial and fibro- 
blastic cells is a cleavage of  the endothelial core protein, e.g., 
by trypsin-like enzymes at the site of  the dibasic sequences in 
the ectodomain, causing its release to the medium, whereas 
the size estimate for the fibroblast proteoglyean pertains to 
the membrane-associated form of the molecule. 
The three members of this proteoglycan family and glypi- 
can,  the  phosphatidylinositol-linked  heparan  sulfate  pro- 
teoglycan, share a  sequence motif in the ectodomain that 
strongly resembles the serine-glycine repeat and flanking se- 
quence of serglycin,  the protein that forms the core of the 
heparin proteoglycan in mast cells (Kjell~n et al., 1989), and 
therefore may serve for the attachment of heparin and hepa- 
ran sulfate chains to these proteins.  The consensus sequence 
of this "glycanation  signal ~ could be read as Acidic-XXX- 
XSGXG (see Fig. 4).  Interestingly,  amino acid 21  of the 
amino terminus of  the endothelial proteoglycan (correspond- 
ing to the serine of the first SG sequence in amphiglycan) ap- 
peared as a blank during protein sequencing (Castillo et al., 
1987),  which suggests that the consensus structure of the 
glycanation signal may perhaps be simplified to the sequence 
Acidic-XXXXSG  or even shorter versions (Acidic-XSG) of 
this sequence. Which sites are glycanated in amphiglycan in 
lung fibroblasts has not been established, but the apparent 
size of the intact proteoglycan in fibroblasts  is such (>200 
kD) that it is likely to contain several heparan sulfate chains. 
On the other hand,  neither amphiglycan  nor fibroglycan, 
which carry only heparan sulfate chains where syndecan also 
carries  chondroitin  sulfate,  have  a  sequence of the type 
Acidic-XSG-Acidic  encountered in syndecan (Saunders et 
al., 1989). It should be noted, however, that in none of these 
cell surface proteoglycans have the glycosylation sites been 
directly identified. 
The most striking  structural similarities  between synde- 
can,  fibroglycan,  and amphiglycan,  which seem to group 
these molecules as members of the same family, occur in the 
membrane-spanning  and cytoplasmic segments of these pro- 
teins  and  includes  the conservation  of four characteristic 
tyrosines. The functional  significance of these structures is 
not known.  However, in polarized epithelial monolayers the 
expression of syndecan becomes confined to the basolateral 
cell surfaces (Rapraeger et al.,  1986), and in confluent hu- 
man lung fibroblasts the different cell surface proteoglycans 
appear  to  be  rapidly  cleared  from  the  cell  surface  and 
degraded,  except glypican,  which  is  shed  (David  et al., 
1990). These observations imply that the conserved domains 
may contain signals  for the targeting  of these proteins (and 
possibly of their associated ligands)  to specific membrane 
and endocytotic compartments, and that as for other mem- 
brane proteins, tyrosine residues may form essential parts of 
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parts of the sequences occur between the first and second and 
around the fourth tyrosine and might therefore support func- 
tions that are  common to all proteoglycan  forms.  Trans- 
fection and  in  situ mutagenesis experiments  may help to 
find experimental support for and clarification of these possi- 
bilities. 
High levels of fibroglycan appear characteristic  for fibro- 
blastic  cells (Lodes et al.,  1992), and syndecan,  although 
transiently  expressed in condensing  mesenchymes  (Bern- 
field and Sanderson,  1990; Vainio et al.,  1991),  seems to 
prevail in epithelia (Hayashi et al.,  1987), but amphiglycan 
shows no clear predilection and is an abundant proteoglycan 
in both cell types. Whether this pattern of expression implies 
that amphiglycan may assume a housekeeping function where 
the other proteoglycans support differentiated  functions is 
unknown.  The  endothelial  proteoglycan  from  which  the 
amino-terminal  sequence data were obtained had been im- 
plicated in the inhibition of the extrinsic coagulation pathway 
(Castillo et al., 1987), suggesting that amphiglycan in these, 
and perhaps in other cells as well, may be involved in the ac- 
tivation of proteinase inhibitors.  Results on the binding of the 
different cell surface proteoglycans of human umbilical vein 
endothelial cells to antithrombin III, however,  suggest that 
this is a property  which is neither  unique nor typical  for 
amphiglycan (Mertens et al.,  manuscript  in preparation). 
Moreover,  in fibroblasts we have failed to detect differences 
between any of the three members of the family in their abili- 
ties to bind to type I collagen or fibronectin (not shown), sug- 
gesting that specifications  in their  respective  functions, if 
any, may reside on (yet unidentified)  properties  or associa- 
tions of the core proteins or in the specific nature of the hepa- 
ran sulfate-dependent processes that are at work in the cells 
where these proteoglycans are expressed. It will also be im- 
portant to determine to what extent  the expression of the 
different proteins may be modulated and by what signals, as 
differential regulatory mechanisms may endow the cells with 
greater  flexibilities  in  their  responses to various effector 
systems that  tune the level of heparan  sulfate  at  the cell 
surface and the processes that depend on it. 
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Note Added in Proof Since the submission of this manuscript a eDNA se- 
quence (available from EMBL/GenBank/DDBJ under accession number 
M81785)  which  codes  for  a  heparan  sulfate  proteoglycan  from  rat 
microvascular endothelial cells and which is probably the equivalent of the 
35K17 sequence has been published (Kojima, T.,  N.  W.  Shworak, and 
R. D. Rosenberg. 1992.  J.  Biol.  Chem.  267:4870-4877). 
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